vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Toast, Inc. (TOST). Click either name above to swap in a different company.

Toast, Inc. is the larger business by last-quarter revenue ($1.6B vs $950.5M, roughly 1.7× Astrana Health, Inc.). Toast, Inc. runs the higher net margin — 6.2% vs 0.7%, a 5.5% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 22.0%). Toast, Inc. produced more free cash flow last quarter ($178.0M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 23.3%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Toast, Inc. is an American cloud-based restaurant management software company based in Boston, Massachusetts. The company provides an all-in-one point of sale (POS) system built on the Android operating system.

ASTH vs TOST — Head-to-Head

Bigger by revenue
TOST
TOST
1.7× larger
TOST
$1.6B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+20.8% gap
ASTH
42.9%
22.0%
TOST
Higher net margin
TOST
TOST
5.5% more per $
TOST
6.2%
0.7%
ASTH
More free cash flow
TOST
TOST
$183.9M more FCF
TOST
$178.0M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
23.3%
TOST

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
TOST
TOST
Revenue
$950.5M
$1.6B
Net Profit
$6.6M
$101.0M
Gross Margin
25.9%
Operating Margin
1.9%
5.2%
Net Margin
0.7%
6.2%
Revenue YoY
42.9%
22.0%
Net Profit YoY
184.4%
215.6%
EPS (diluted)
$0.12
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
TOST
TOST
Q4 25
$950.5M
$1.6B
Q3 25
$956.0M
$1.6B
Q2 25
$654.8M
$1.6B
Q1 25
$620.4M
$1.3B
Q4 24
$665.2M
$1.3B
Q3 24
$478.7M
$1.3B
Q2 24
$486.3M
$1.2B
Q1 24
$404.4M
$1.1B
Net Profit
ASTH
ASTH
TOST
TOST
Q4 25
$6.6M
$101.0M
Q3 25
$373.0K
$105.0M
Q2 25
$9.4M
$80.0M
Q1 25
$6.7M
$56.0M
Q4 24
$-7.8M
$32.0M
Q3 24
$16.1M
$56.0M
Q2 24
$19.2M
$14.0M
Q1 24
$14.8M
$-83.0M
Gross Margin
ASTH
ASTH
TOST
TOST
Q4 25
25.9%
Q3 25
26.5%
Q2 25
25.3%
Q1 25
25.9%
Q4 24
24.9%
Q3 24
24.7%
Q2 24
23.0%
Q1 24
23.2%
Operating Margin
ASTH
ASTH
TOST
TOST
Q4 25
1.9%
5.2%
Q3 25
2.0%
5.1%
Q2 25
3.1%
5.2%
Q1 25
3.3%
3.2%
Q4 24
0.1%
2.5%
Q3 24
5.9%
2.6%
Q2 24
6.2%
0.4%
Q1 24
7.5%
-5.2%
Net Margin
ASTH
ASTH
TOST
TOST
Q4 25
0.7%
6.2%
Q3 25
0.0%
6.4%
Q2 25
1.4%
5.2%
Q1 25
1.1%
4.2%
Q4 24
-1.2%
2.4%
Q3 24
3.4%
4.3%
Q2 24
3.9%
1.1%
Q1 24
3.7%
-7.7%
EPS (diluted)
ASTH
ASTH
TOST
TOST
Q4 25
$0.12
$0.18
Q3 25
$0.01
$0.16
Q2 25
$0.19
$0.13
Q1 25
$0.14
$0.09
Q4 24
$-0.14
$0.09
Q3 24
$0.33
$0.07
Q2 24
$0.40
$0.02
Q1 24
$0.31
$-0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
TOST
TOST
Cash + ST InvestmentsLiquidity on hand
$429.5M
$1.4B
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$2.1B
Total Assets
$2.2B
$3.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
TOST
TOST
Q4 25
$429.5M
$1.4B
Q3 25
$463.4M
$1.4B
Q2 25
$342.1M
$1.2B
Q1 25
$260.9M
$1.0B
Q4 24
$290.8M
$903.0M
Q3 24
$350.3M
$761.0M
Q2 24
$327.7M
$691.0M
Q1 24
$337.3M
$578.0M
Stockholders' Equity
ASTH
ASTH
TOST
TOST
Q4 25
$779.3M
$2.1B
Q3 25
$775.5M
$2.0B
Q2 25
$765.5M
$1.8B
Q1 25
$745.4M
$1.7B
Q4 24
$712.7M
$1.5B
Q3 24
$704.6M
$1.4B
Q2 24
$678.9M
$1.3B
Q1 24
$653.5M
$1.2B
Total Assets
ASTH
ASTH
TOST
TOST
Q4 25
$2.2B
$3.1B
Q3 25
$2.2B
$3.0B
Q2 25
$1.4B
$2.8B
Q1 25
$1.3B
$2.6B
Q4 24
$1.4B
$2.4B
Q3 24
$1.3B
$2.2B
Q2 24
$1.3B
$2.2B
Q1 24
$1.2B
$2.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
TOST
TOST
Operating Cash FlowLast quarter
$-2.9M
$194.0M
Free Cash FlowOCF − Capex
$-6.0M
$178.0M
FCF MarginFCF / Revenue
-0.6%
10.9%
Capex IntensityCapex / Revenue
0.3%
1.0%
Cash ConversionOCF / Net Profit
-0.44×
1.92×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$608.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
TOST
TOST
Q4 25
$-2.9M
$194.0M
Q3 25
$10.0M
$165.0M
Q2 25
$90.9M
$223.0M
Q1 25
$16.6M
$79.0M
Q4 24
$-10.9M
$147.0M
Q3 24
$34.0M
$109.0M
Q2 24
$23.2M
$124.0M
Q1 24
$6.0M
$-20.0M
Free Cash Flow
ASTH
ASTH
TOST
TOST
Q4 25
$-6.0M
$178.0M
Q3 25
$7.4M
$153.0M
Q2 25
$89.5M
$208.0M
Q1 25
$13.6M
$69.0M
Q4 24
$-13.5M
$134.0M
Q3 24
$31.7M
$97.0M
Q2 24
$20.4M
$108.0M
Q1 24
$5.6M
$-33.0M
FCF Margin
ASTH
ASTH
TOST
TOST
Q4 25
-0.6%
10.9%
Q3 25
0.8%
9.4%
Q2 25
13.7%
13.4%
Q1 25
2.2%
5.2%
Q4 24
-2.0%
10.0%
Q3 24
6.6%
7.4%
Q2 24
4.2%
8.7%
Q1 24
1.4%
-3.1%
Capex Intensity
ASTH
ASTH
TOST
TOST
Q4 25
0.3%
1.0%
Q3 25
0.3%
0.7%
Q2 25
0.2%
1.0%
Q1 25
0.5%
0.7%
Q4 24
0.4%
1.0%
Q3 24
0.5%
0.9%
Q2 24
0.6%
1.3%
Q1 24
0.1%
1.2%
Cash Conversion
ASTH
ASTH
TOST
TOST
Q4 25
-0.44×
1.92×
Q3 25
26.69×
1.57×
Q2 25
9.65×
2.79×
Q1 25
2.48×
1.41×
Q4 24
4.59×
Q3 24
2.11×
1.95×
Q2 24
1.21×
8.86×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

TOST
TOST

Technology Service$1.3B82%
License$256.0M16%
Product And Professional Services$43.0M3%

Related Comparisons